In 2005, 1.37 million new cancer patients were diagnosed and 570,000 cancer-related deaths were recorded in the United States, confirming cancer as the second leading cause of death. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Tumors invade healthy tissue and their unchecked growth and spread results in death.
Historically, cancer treatment focused on cytotoxic drugs that cause cell death of both cancerous and non-cancerous tissue. Progress over the last decade has resulted in a better understanding of the biochemical pathways and the recent emergence of targeted therapies that reduce tumor burden while sparing healthy tissue. Despite these advancements, many current treatment regimens still include radiation and chemotherapy, which are frequently associated with serious and life threatening side effects.
Kalypsys is leveraging detailed knowledge of the biochemical pathways and mechanisms that regulate tumor cell growth to develop therapies that selectively target cancer cells. Our lead program, KD5170, is an orally administered histone deacetylase (HDAC) inhibitor for the treatment of hematologic and solid tumors.